VOLITIONRX LTD(VNRX)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
VOLITIONRX LTD (VNRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VNRX at 26.1/100 on a 32-signal composite quality model, placing it at rank #2,633 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), VOLITIONRX LTD reports quarterly revenue of $398.7K, net income of $-7.3M, free cash flow of $-5.2M. Top institutional holders of VNRX by reported 13-F value include Lagoda Investment Management, L.P., LUMINUS MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. VNRX trades on the NYSE exchange and files with the SEC under CIK 93314. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VOLITIONRX LTD directly from SEC EDGAR.
AI Quality Score
26.1/100
AI Rank
#2,633
Revenue
$398.7K
Net Income
$-7.3M
Free Cash Flow
$-5.2M
VNRX key financials by period
VOLITIONRX LTD reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.7M
$-23.4M
—
FY 2024
10-K
$1.2M
$-27.0M
—
FY 2023
10-K
$775.3K
$-35.7M
—
FY 2022
10-K
$306.4K
$-30.6M
—
FY 2021
10-K
$90.0K
$137.0M
—
FY 2020
10-K
$13.4K
$110.2M
—
Institutions holding VNRX
Institutional investors reporting a position in VOLITIONRX LTD on SEC Form 13F.
